Saxenda vs Wegovy Cost: Which Weight Loss Drug Is More Affordable

Wegovy is generally more expensive upfront — around $1,300–$1,450 per month without insurance versus Saxenda's $1,200–$1,350 — but Wegovy is a once-weekly injection while Saxenda requires a daily injection. When you factor in the stronger weight loss results seen in clinical trials, many people and insurers consider Wegovy the higher-value option despite the similar sticker price.

What Does Each Drug Actually Cost Without Insurance?

List prices fluctuate, but here are current U.S. retail estimates based on pharmacy pricing data as of 2025:

The gap between the two is surprisingly narrow — roughly $100–$150 per month. Neither drug has a generic available in the United States. Saxenda's manufacturer, Novo Nordisk, also makes Wegovy, which means both are subject to similar pricing structures and patent protections.

How Do Manufacturer Savings Programs Compare?

Both drugs come with manufacturer-sponsored savings cards for commercially insured patients. Here is how they break down:

• Wegovy Savings Offer (Novo Nordisk): Eligible patients with commercial insurance may pay as little as $0 for a 28-day supply, depending on benefit coverage. Patients without insurance are not eligible for the card but may access Novo Nordisk's NovoCare patient assistance program if they meet income criteria.
• Saxenda Savings Card (Novo Nordisk): Commercially insured patients may reduce their out-of-pocket cost significantly — in some cases to as low as $25 per month. Uninsured patients can explore the same NovoCare assistance pathway.

The practical takeaway: if you have commercial insurance that covers either drug, both can be made affordable through the savings card. If you are uninsured or on government insurance such as Medicare or Medicaid, the calculus changes significantly. Medicare's coverage rules for Wegovy changed in 2026, which may affect which option makes sense for older adults.

Does Insurance Cover Saxenda and Wegovy Differently?

Coverage depends heavily on your plan, but there are notable patterns:

• Saxenda has been on the market since 2014, giving it a longer track record with payers. Some plans that still exclude newer GLP-1 drugs may cover Saxenda under an older obesity medication tier.
• Wegovy received FDA approval in 2021 and is specifically approved for chronic weight management. Many large employers added it to formularies after the STEP 1 trial showed an average of approximately 14.9% body weight reduction over 68 weeks (Wilding et al., NEJM, 2021). However, some plans impose step-therapy requirements — meaning you may need to try and fail Saxenda first before Wegovy is approved.
• Medicare Part D historically excluded weight loss drugs, but the Inflation Reduction Act and related rulemakings have begun to shift this landscape for Wegovy specifically in the context of cardiovascular risk reduction.

How Does the Cost-Per-Pound-Lost Compare?

Raw price comparisons miss the efficiency question. In separate pivotal trials, the two drugs showed meaningfully different weight loss outcomes:

• Saxenda: In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM, 2015), patients lost an average of approximately 8% of body weight over 56 weeks at the 3.0 mg maintenance dose.
• Wegovy: In the STEP 1 trial (Wilding et al., NEJM, 2021), patients lost an average of approximately 14.9% of body weight over 68 weeks at the 2.4 mg maintenance dose.

These trials cannot be directly compared head-to-head — different populations, different durations — but the magnitude of difference is large enough that many endocrinologists and payers view Wegovy as delivering greater clinical return per dollar spent over the long term, even at a slightly higher sticker price.

What Is the Dose Escalation Timeline and How Does It Affect Cost?

Both drugs require gradual dose escalation to reduce side effects. The timeline affects how many pens or cartridges you use each month, which can influence early-phase costs.

Saxenda's lower starting doses mean the first one to two months may cost slightly less at the pharmacy counter. However, Wegovy's once-weekly injection schedule means fewer pens purchased per month overall, which simplifies supply management and can reduce dispensing fees at some pharmacies.

Are There Any Lower-Cost Alternatives to Consider?

If neither drug is affordable out of pocket, a few options are worth discussing with your prescriber:

• Compounded semaglutide or liraglutide: During shortage periods, FDA-registered compounding pharmacies have been permitted to produce versions of these drugs. Costs can be significantly lower — sometimes $200–$400 per month — but compounded versions are not FDA-approved and quality can vary. The FDA has signaled it will restrict this pathway as branded supply normalizes.
• Ozempic (semaglutide 0.5–2 mg): The same active ingredient as Wegovy but approved for type 2 diabetes. Some prescribers write it off-label for weight loss. It carries the same savings card structure and is sometimes priced similarly. See how Wegovy and Ozempic compare in terms of approved doses and indications.
• Patient assistance programs: NovoCare (for Saxenda and Wegovy) and similar programs from other manufacturers offer free or reduced-cost medication to patients below certain income thresholds. Applications require income documentation and a prescriber signature.

Frequently Asked Questions

Cost is one of the most important practical factors in any long-term medication decision — but the right answer depends on your insurance plan, your health history, and your prescriber's clinical judgment. Before starting either Saxenda or Wegovy, ask your prescriber and pharmacist to walk through your specific coverage, run a prior authorization check, and apply for the relevant savings program. A small amount of upfront research can mean hundreds of dollars in monthly savings.